Valeo Pharma Inc.

VPH

CA91915B1085

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

Sector

Pharmaceuticals

Calendar

10/09/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.13 CAD

Average target price

0.45 CAD

Spread / Average Target

+246.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VALEO PHARMA INC.	-27.78%	9.36M
ELI LILLY AND COMPANY	+52.93%	803B
NOVO NORDISK A/S	+41.20%	631B
JOHNSON & JOHNSON	-7.08%	351B
MERCK & CO., INC.	+17.40%	324B
ABBVIE INC.	+10.58%	303B
ASTRAZENECA PLC	+16.74%	243B
ROCHE HOLDING AG	+2.13%	228B
NOVARTIS AG	+10.19%	217B
AMGEN INC.	+6.24%	164B

Other Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 16:45:15 19/06/2024 BST			5-day change	1st Jan Change
0.13 ^CAD	-7.14%		+18.18%	-27.78%

06-18	Valeo Pharma Names Chief Development Officer; Up Nearly 22%	MT
06-18	Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors	CI

Valeo Pharma Names Chief Development Officer; Up Nearly 22%	06-18	MT
Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors	06-18	CI
Transcript : Valeo Pharma Inc., Q2 2024 Earnings Call, Jun 14, 2024	06-14
Valeo Pharma Fiscal Q2 Loss Widens 21% as Expenses Increase; Revenue Up 4%	06-14	MT
Valeo Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	06-13	CI
Toronto Stocks Retreat; ADF Group Shares Fall on C$47.9 Million Buyback from Certain Board Members	06-13	DJ
Valeo Pharma Restructures Commercial Field Operations to Lower Expenses	06-13	MT
Valeo Pharma Announces Restructuring of Commercial Field Operations to Support Path to Profitability	06-13	CI
Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call	04-25
Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors	03-22	CI
Transcript : Valeo Pharma Inc., Q1 2024 Earnings Call, Mar 15, 2024	03-15
Valeo Pharma Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	03-14	CI
Valeo Pharma Inc. Announces Board Changes	02-13	CI
Valeo Pharma Brief: Notes Sagard credit facility amended to provide for early repayments and liquidity requirements in fiscal 2024	02-02	MT
Valeo Pharma Brief: Says Proceeds from reimbursement to be used for debt reduction purposes	02-02	MT
Valeo Pharma Brief: Adding SIMBRINZA remains under Valeo Pharma exclusive promotion and distribution	02-02	MT
Valeo Pharma Brief: Says Original commercialization and supply agreement amended following global divestment of XIIDRA	02-02	MT
Valeo Pharma Brief: Amending Agreement With Novartis Pharmaceuticals Canada For XIIDRA In Canada, and Credit Facility With Sagard Healthcare Royalty Partners, LP	02-02	MT
Valeo Pharma Amends Agreement with Novartis Pharmaceuticals Canada for (Pr)XIIDRA in Canada	02-02	CI
Valeo Pharma Inc. Amends Credit Facility with Sagard Healthcare Partners, LP	02-02	CI
Transcript : Valeo Pharma Inc., Q4 2023 Earnings Call, Jan 30, 2024	01-30
Valeo Pharma's Q4'23 Net Loss Holds Steady YOY	01-30	MT
Valeo Pharma Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	01-29	CI
North American Morning Briefing : Cautious Start to Fully-Booked Week	01-29	DJ
LSL Pharma Group Appoints Luc Mainville as Chief Financial Officer	12-04	MT

Valeo Pharma Inc.

Equities

VPH